InsidersTradesSigma
Cyteir Therapeutics, Inc.: insider trades · United States · SEC (Form 4)
SEC:cyteir-therapeutics-inc-72cf9fUS·SEC (Form 4)
Discover the full directors' dealings record of Cyteir Therapeutics, Inc., a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). The latest transaction was reported on 16 May 2022 (Acquisition). Among the most active insiders: Zakrzewski Joseph S. All data is accessible without an account.
23
Insider Decl.
0
Thresholds
€152,954
9 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
Last declaration on 16 May 2022
Declarations23 total
Executives▲Purchase33SEC
€1,152743 shares@ €1.55110.9% of flow
Common Stock
SEC:0001209191-22-029135:0·
Ideal exit: 6 Feb 2023 (T+270)
Executives▲Purchase40SEC
€88,65249,406 shares@ €1.794466.2% of flow
Common Stock
SEC:0001209191-22-028574:0·
Ideal exit: 4 Feb 2023 (T+270)
Executives▲Purchase35SEC
€18,98810,000 shares@ €1.8988100.0% of flow
Common Stock
SEC:0001209191-22-028578:0·
Ideal exit: 4 Feb 2023 (T+270)
Executives▲Purchase18SEC
€1,742200 shares@ €8.71227.9% of flow
Common Stock
SEC:0000899243-21-049973·
Ideal exit: 19 Sept 2022 (T+270)
Executives▲Purchase21SEC
€1,742200 shares@ €8.71221.3% of flow
Common Stock
SEC:0000899243-21-049973:0·
Ideal exit: 19 Sept 2022 (T+270)
Executives▲Purchase16SEC
€1,743200 shares@ €8.7177.9% of flow
Common Stock
SEC:0000899243-21-049198·
Ideal exit: 13 Sept 2022 (T+270)
Executives▲Purchase19SEC
€1,743200 shares@ €8.7171.3% of flow
Common Stock
SEC:0000899243-21-049198:0·
Ideal exit: 13 Sept 2022 (T+270)
Executives▲Purchase21SEC
€18,5952,000 shares@ €9.297484.2% of flow
Common Stock
SEC:0000899243-21-048432·
Ideal exit: 11 Sept 2022 (T+270)
Executives▲Purchase16SEC
€18,5952,000 shares@ €9.297413.9% of flow
Common Stock
SEC:0000899243-21-048432:0·
Ideal exit: 11 Sept 2022 (T+270)
Executives●C2SEC
3,259,025 shares
Common Stock
SEC:0001209191-21-042724:0·
23 of 23 declarations
